ABBV-916

DRUG2 trials

Sponsors

Abbvie Deutschland GmbH & Co. KG, AbbVie

Conditions

Alzheimer's Disease (AD)Alzheimer's disease (AD)

Phase 2

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

CompletedNCT05291234

AbbVieAlzheimer's Disease (AD)

Start: 2022-08-15End: 2025-11-19Updated: 2025-12-10

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease

CompletedCTIS2022-500691-59-00

Abbvie Deutschland GmbH & Co. KGAlzheimer's disease (AD)

End: 2024-06-27Target: 98Updated: 2024-06-03

Related Papers

HARBOR: ABBV-916 In Subjects With Early Alzheimer’s Disease Combined Multiple-Ascending Dose/Proof-Of-Concept Study Design (P7-6.008)

Neurology2023-04-25